Work

Discovery of potential small molecule inhibitors against β-hCG: an in silico study with in vitro validation

Year: 2025

Type: article

Abstract: of 32 μM. This is the first study to report the anticancer activity of cefotetan, an FDA-approved drug used to treat bacterial infections, and this drug could be repurposed as a targeted therapeutic against β-hCG expressing cancers. Findings of this study hold significant implications for developing potential therapeutic interventions, which target β-hCG in the context of BRCA1-defective breast cancers, aligning with the broader goal of advancing precision medicine in oncology.

Source: RSC Advances

DOI: 10.1039/d4ra08663e

Authors: Shreya Sara Ittycheria, Krishnankutty Chandrika Sivakumar, Dipyaman Patra, Bhavana Ramachandran, R. L. Neetha, Arathy V. Warrier, M. A. Aiswariya, S. Kaviya, Pankaj Suman, Nagarjun Narayanaswamy, Priya Srinivas

Institutions: Manipal Academy of Higher Education, Rajiv Gandhi Centre for Biotechnology, University of Kerala, Regional Centre for Biotechnology, National Institute of Animal Biotechnology

Language: English

Topic: Computational Drug Discovery Methods

Subfield: Computational Theory and Mathematics

Field: Computer Science

Domain: Physical Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $1,042

Funders: Rajiv Gandhi Centre for Biotechnology, Department of Biotechnology, Ministry of Science and Technology, India, Indian Council of Medical Research, Council of Scientific and Industrial Research, India

Awards: G2442139129, G3174220521

OpenAlex ID: W4411188477

FWCI:

Cites: 27

Cited by:

Related to: 10